Health Care/Hospital

Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics

* The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species across thousands of sites globally. * By partnering with Anthropic, Ultima Genomics, and PacBio, and powered by NVIDIA AI infrastructure, Basecamp Research aim...

2026-03-18 17:00 3569

LEIFRAS Co., Ltd. Obtains Membership with the Nippon Sport Policy Commission

To Support National Sports Policy and Accelerate Community-Based Transition of School Club Activities TOKYO, March 18, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or "Leifras"), a sports and social business company dedicated to youth sports and community engagement, is pl...

2026-03-18 15:00 3875

ProtectHealth strengthen PeKa b40 health screening promotion with Hospital Shah Alam staff in Program Ziarah MADANI

SHAH ALAM, Malaysia, March 18, 2026 /PRNewswire/ -- ProtectHealth Corporation Sdn. Bhd., as an implementing agency under the Ministry of Health Malaysia (MOH), continues to strengthen efforts to promote the Skim Peduli Kesihatan for the B40 group during the Program Ziarah MADANI at Hospital Shah ...

2026-03-18 14:26 4154

2026 International Academicians Hong Kong Forum to be Held on April 14: Gathering Global Wisdom to Chart a New Blueprint for AI-Empowered Health and Higher Education

HONG KONG, March 18, 2026 /PRNewswire/ -- Jointly organized by the International Alliance of Academicians (IAA) and the Hong Kong Association of Overseas-Returned Scholars (HKAORS), the 2026 International Academicians Hong Kong Forum will take place on 14 April at the Grand Hyatt Hong Kong. The F...

2026-03-18 12:50 1063

Innodisk at NVIDIA GTC 2026: Accelerating Real-World AI for Healthcare and Mobility with Full-Stack Edge Solutions

SAN JOSE, Calif., March 18, 2026 /PRNewswire/ -- Innodisk, a leading global AI solution provider, today announced its participation in NVIDIA GTC 2026. Alongside subsidiary Aetina, Innodisk Group is showcasing the seamless integration of NVIDIA AI architectures into scalable, deployable edge AI ...

2026-03-18 11:32 5719

Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited

SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a letter of...

2026-03-18 11:07 9562

North London Collegiate School (Singapore) Student Achieves Academic Milestone with Peer-Reviewed Journal Publication

Saket Subramaniam of North London Collegiate School (Singapore) publishes peer-reviewed medical research on colorectal cancer liver metastasis in the American Journal of Student Research. SINGAPORE, March 18, 2026 /PRNewswire/ -- North London Collegiate School (Singapore) celebrates the remarkab...

2026-03-18 10:00 5031

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

SHANGHAI and HONG KONG, March 18, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...

2026-03-18 08:30 5611

Vieworks to Debut VISQUE DPS LH210 at USCAP 2026, a Single Scanner for Both Cytology and Histology

High-throughput, mid capacity LH210 expands the VISQUE DPS lineup with fast scanning, optimized data size, and scalable digital pathology workflow ANYANG, South Korea, March 18, 2026 /PRNewswire/ -- Vieworks, a global provider of advanced imaging solutions, will participate inUSCAP 2026 (United ...

2026-03-18 07:30 3827

Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy

TAIPEI and SAN DIEGO, March 17, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its first-in-class investigational drug Pidnarule...

2026-03-18 07:00 6794

Health In Tech and Amazon Web Service Advanced Tier Service Partner Ciklum Announce Strategic Collaboration to Accelerate Development of AI-Driven InsurTech Platform

STUART, Fla., March 17, 2026 /PRNewswire/ -- Health In Tech, Inc. (the "Company" or "Health In Tech") (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced a strategic collaboration with Ciklum, a global AI-powered experience engineering and softwar...

2026-03-18 04:01 7762

Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform. HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical‑st...

2026-03-17 21:30 3471

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

HIGHLIGHTS * Oral presentation on key results from the Co-PSMA (NCT06907641 )[1] Investigator-Initiated Trial (IIT) was delivered by ProfLouise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the ...

2026-03-17 21:01 6177

Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson's Research

Partnership supports expanded biomarker discovery efforts within MJFF's Parkinson's Progression Markers Initiative MORRISVILLE, N.C., March 17, 2026 /PRNewswire/ -- Metabolon , ...

2026-03-17 21:00 3975

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therap...

2026-03-17 20:00 6301

Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models

- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50  for human amylin 1 receptor (hAMY1R) was 21.4 pM and 21.2 pM for ASC39 and elo...

2026-03-17 18:00 5856

/C O R R E C T I O N -- Gesynta Pharma/

In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as incorrectly transmitted by PR Newswire. The complete, cor...

2026-03-17 17:24 7709

Global Aesthetic Trends Evolve Toward 'Anti-Sagging': The Expansion of the Structural Skin Laxity Improvement and Liquid Type PCL Collagen Stimulator Market

SEOUL, South Korea, March 17, 2026 /PRNewswire/ -- The global medical aesthetics market is rapidly shifting toward an "Anti-Sagging" paradigm, focusing on improving the fundamental causes of skin laxity. While traditional aesthetic approaches primarily addressed external signs of aging—such as w...

2026-03-17 12:33 4692

Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleo...

2026-03-17 11:00 5944

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027

SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) tar...

2026-03-17 10:32 6198
1 ... 33343536373839 ... 858